Clinical efficacy of Danggui Sini Decoction for treatment of lower limb arteriosclerosis obliterans: A randomized controlled trial

BACKGROUND: Endovascular revascularization for lower limb arteriosclerosis obliterans (ASO) is often limited by long-term restenosis. This study evaluated whether the traditional Chinese medicine formula Danggui Sini Decoction (DGSD) could improve mid-term outcomes when combined with the standard procedure. AIM: To investigate the clinical efficacy of DGSD combined with endovascular revascularization in the treatment of ASO and its impact on patients' quality of life. METHODS: A total of 38 ASO patients treated at Zhangjiajie People's Hospital from January 2023 to January 2025 were selected and randomly divided into a control group and an experimental group, with 19 patients in each group. The control group received conventional endovascular revascularization and basic treatment, while the experimental group was treated with DGSD in addition to the control group's treatment. The clinical effectiveness rate, freedom from clinically driven target lesion revascularization, primary patency rate, and quality of life scores were compared between the two groups. RESULTS: < 0.05). CONCLUSION: DGSD combined with endovascular revascularization can significantly improve the mid-term clinical efficacy in ASO patients, reduce the risk of lower limb arterial re-occlusion, and enhance quality of life, demonstrating significant clinical application value.